Phylogica’s biological “peptide” vaccine has performed the best in coaxing an immune response against HSV during animal testing, with 75% of the mice treated with its peptides mated to a common HSV antigen showing no detectable signs of the virus. The company will now pit its peptide vaccine against Swiss company Amal Therapeutics’ zebra CPP with results expected in the first quarter of 2019.
Related Data & Insights
-
-
Rank Company Revenue 87th PYC Therapeutics $15.8m 90th GreenHy2 $15.0m 91st K2fly $14.8m 93rd Advanced Braking Technology $14.7m 94th DTI Group $13.3m 201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
14 Mar 2024
PYC taps investors for $75m
11 May 2023
Perth biotech company raises $30m
07 Nov 2022
Healthtech banks on rising numbers
15 Jul 2022
Exal Group buys $44m Freo warehouse
13 May 2022
Hockings hopes for blindness drug
06 May 2022
Riches takes top spot at 40under40 awards
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX